

# MEDICAL POLICY



MEDICAL POLICY DETAILS	
Medical Policy Title	Cardiac/Coronary Computed Tomographic Angiography (Cardiac/Coronary CTA): Contrast-Enhanced
Policy Number	6.01.34
Category	Technology Assessment
Original Effective Date	06/16/05
Committee Approval Date	09/21/06, 09/20/07, 09/18/08, 09/17/09, 06/17/10, 06/16/11, 07/19/12, 10/17/13, 06/19/14, 01/22/15, 04/21/16, 06/15/17, 06/21/18, 07/18/19, 10/22/20, 08/19/21, 04/21/22, 04/20/23, 12/21/23
Current Effective Date	04/15/24
Archived Date	N/A
Archive Review Date	N/A
Product Disclaimer	<ul style="list-style-type: none"> <li>• <i>If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.</i></li> <li>• <i>If a commercial product (including an Essential Plan or Child Health Plus product), medical policy criteria apply to the benefit.</i></li> <li>• <i>If a Medicaid product covers a specific service, and there are no New York State Medicaid guidelines (eMedNY) criteria, medical policy criteria apply to the benefit.</i></li> <li>• <i>If a Medicare product (including Medicare HMO-Dual Special Needs Program (DSNP) product) covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.</i></li> <li>• <i>If a Medicare HMO-Dual Special Needs Program (DSNP) product DOES NOT cover a specific service, please refer to the Medicaid Product coverage line.</i></li> </ul>

## POLICY STATEMENT

- I. Based upon our criteria and assessment of the peer-reviewed literature, cardiac computed tomographic angiography (CCTA), is considered **medically appropriate** for **ANY** of the following:
  - A. Cardiac CT for structure and morphology:
    1. Cardiac vein identification for lead placement in individuals needing left ventricular pacing. **OR**
    2. Evaluation of the anatomy of the pulmonary veins prior to an ablation procedure for atrial fibrillation. **OR**
    3. Evaluation of cardiac or pericardial mass or tumor, cardiac thrombus, complications of cardiac surgery and/or pericarditis or constrictive pericarditis when an echocardiogram was performed and is inconclusive. **OR**
    4. In place of magnetic resonance imaging (MRI) when there is clinical suspicion of suspected arrhythmogenic right ventricular dysplasia (ARVD) or arrhythmogenic cardiomyopathy (ARVC) with presyncope or syncope, when clinical suspicion is supported by established criteria for ARVD. **OR**
    5. Recurrent laryngeal nerve palsy due to cardiac chamber enlargement. **OR**
    6. In place of transesophageal echocardiogram (TEE) for assessment of left atrial appendage (LAA) occlusion device or to assess for thrombus.
  - B. Cardiac CT for congenital heart disease:
    1. Coronary artery anomaly evaluation, when a cardiac catheterization was performed, and not all coronary arteries were identified.
    2. Thoracic arteriovenous anomaly evaluation, when a cardiac MRI or chest CT angiogram was performed and suggested congenital heart disease.

**Medical Policy: CARDIAC/CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY  
(CARDIAC/CORONARY CTA): CONTRAST-ENHANCED**

**Policy Number: 6.01.34**

**Page: 2 of 9**

3. Complex adult congenital heart disease evaluation, when no cardiac CT or cardiac MRI has been performed, and there is a contraindication to cardiac MRI, or cardiac CT or cardiac MRI was performed one (1) or more years ago.

**C. Cardiac CTA:**

1. For new, recurrent or worsening likely anginal symptoms as defined by chest, epigastric, shoulder, arm/jaw pain, chest pressure/discomfort.
2. For new, recurrent or worsening symptoms of chest pain, exertional dyspnea, or exertional fatigue and **ANY** of the following:
  - a. Persistent symptoms after a normal stress test; **OR**
  - b. Equivocal, borderline, abnormal or discordant prior noninvasive evaluation where obstructive CAD disease remains a concern (less than 90 days); **OR**
  - c. Abnormal rest ECG findings, such as a new left bundle branch block (LBBB), or T-wave inversions, when ischemia is a concern; **OR**
  - d. A prior coronary artery bypass graft (CABG) when only a graft patency is a concern.
3. Evaluation of an individual under 40 years of age for suspected anomalous coronary artery(ies) or for the treatment planning when there is a history of **one or more** of the following:
  - a. Syncopal episodes during strenuous activities. **OR**
  - b. Persistent chest pain brought on by exertion or emotional stress, and normal stress test; **OR**
  - c. Full sibling(s) with history of sudden death syndrome before age 40 or with documented anomalous coronary artery; **OR**
  - d. Resuscitated sudden death and contraindications for conventional coronary angiography; **OR**
  - e. Prior nondiagnostic coronary angiography in determining the course of anomalous coronary artery in relation to the great vessels, origin of a coronary artery, or bypass graft location;
4. Initial imaging study for individuals with hypertrophic cardiomyopathy and stable anginal symptoms.
5. Individuals who have recovered from unexplained sudden cardiac arrest in lieu of invasive coronary angiography when **both** of the following are determined:
  - a. confirm the presence or absence of ischemic heart disease **AND**
  - b. exclude the presence of an anomalous coronary artery.
6. Unclear coronary artery anatomy despite conventional cardiac catheterization.
7. Re-do coronary artery bypass grafting (CABG) for **either** of the following:
  - a. Assess bypass graft patency. **OR**
  - b. To evaluate the location of the left internal mammary artery (LIMA) and/or right internal mammary artery (RIMA) prior to repeat bypass surgery.
8. To evaluate left main stent one time at six (6) to twelve (12) months.
9. To evaluate coronary artery anomalies and other complex congenital heart diseases of cardiac chambers or great vessels.
10. Evaluation of newly diagnosed congestive heart failure or cardiomyopathy with all of the following:
  - a. No prior history of coronary artery disease, the ejection fraction is less than 50%, and low or intermediate risk on the pre-test probability assessment; **AND**
  - b. No contraindications to cardiac CT angiography; **AND**
  - c. No cardiac catheterization, single-photon emission CT (SPECT), cardiac positron emission tomography (PET), or stress echocardiogram has been performed since the diagnosis of congestive heart failure or cardiomyopathy.
11. Cardiac CTA will replace conventional invasive coronary angiography for the following indications:
  - a. Ventricular Tachycardia (six (6) beat runs or greater); **OR**
  - b. Delayed presentation or retrospective evaluation of suspected Takotsubo syndrome (stress cardiomyopathy); **OR**
  - c. Preoperative assessment of the coronary arteries in planned surgery for **any** of the following:
    - i. aortic dissection, **OR**
    - ii. aortic aneurysm, **OR**

**Medical Policy: CARDIAC/CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY  
(CARDIAC/CORONARY CTA): CONTRAST-ENHANCED**

**Policy Number: 6.01.34**

**Page: 3 of 9**

- iii. valvular surgery, **OR**
- iv. liver transplant (for initial pre-treatment evaluation and may be repeated once in three (3) years).
- 12. To assess coronary involvement in individuals with systemic vasculitis (e.g., Giant Cell Arteritis, Takayasu's, Kawasaki's disease) when there are clinical features suggestive of underlying vasculitis including:
  - a. Unexplained elevated cardiac markers (erythrocyte sedimentation rate, C-reactive protein). **OR**
  - b. Constitutional symptoms (fevers, chills, night sweats, weight loss). **OR**
  - c. Multiple visceral infarcts in the absence of embolic etiology.
- D. **Cardiac Trauma:** To detect aortic and coronary injury and potentially aid in the evaluation of myocardial and pericardial injury.
- E. **Transplant:** For preoperative assessment for planned liver or kidney transplant.
- F. The following imaging may be used for pre-surgical aortic valve replacement to determine if the individual is a candidate for a Transcatheter Aortic Valve Replacement (TAVR):
  - 1. Cardiac CT- to measure the aortic annulus **OR**
  - 2. Coronary CTA- to measure the aortic annulus and assess the coronary arteries in lieu of heart catheterization.
- G. Post-TAVR cardiac CT:
  - 1. Post-TAVR Transthoracic Echocardiography (TTEs) is indeterminate or raises concerns about valve thrombosis, infective endocarditis, or structural degeneration. **OR**
  - 2. When a valve in valve implantation or surgical re-do AVR Is being contemplated. **OR**
  - 3. For routine CT surveillance or follow up for incidental hypoattenuated leaflet thickening (HALT) with or without restricted leaflet motion, also known as hypoattenuation Affecting Motion (HAM) is NOT recommended.
- II. Based upon our criteria and assessment of the peer-reviewed literature, the use of noninvasive fractional flow reserve (FFR) is considered **medically appropriate** to further assess CAD seen on a recent coronary CTA that is of uncertain physiologic significance.
- III. Based upon our criteria and assessment of the peer-reviewed literature, the use of automated quantification and characterization of coronary atherosclerotic plaque via cardiac CT and CTA is considered **investigational**.
- IV. Based upon our criteria and assessment of the peer-reviewed literature, cardiac CTA is considered **investigational** for all other indications.

*Refer to Corporate Medical Policy #6.01.13 Coronary Calcium Scoring*

*Refer to Corporate Medical Policy #11.01.03 Experimental or Investigational Services*

*Refer to Corporate Medical Policy #11.01.10 Clinical Trials*

**POLICY GUIDELINES**

- I. Ischemic evaluation symptoms can be defined as the following:
  - A. Cardiac chest pain/pressure/tightness (likely anginal symptoms): Chest, epigastric, shoulder, arm, jaw pain, chest pressure/discomfort occurring with exertion or emotional stress and relieved by rest, nitroglycerin, or both.
  - B. Less likely anginal symptoms: Symptoms including dyspnea or fatigue when not exertional and not relieved by rest/nitroglycerin; also includes generalized fatigue or chest discomfort occurring in a time course not suggestive

**Medical Policy: CARDIAC/CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY  
(CARDIAC/CORONARY CTA): CONTRAST-ENHANCED**

**Policy Number: 6.01.34**

**Page: 4 of 9**

- of angina (e.g., resolves spontaneously within seconds or lasts for an extended period and is unrelated to exertion).
- C. Noncardiac explanation: An alternative diagnosis, such as gastroesophageal reflux, chest trauma, anemia, chronic obstructive pulmonary disease, or pleurisy, is present and is the most likely explanation for the patient's symptoms.
- D. Anginal equivalents (individuals with previously documented CAD only):
- Symptoms consistent with individual's known angina pattern in an individual with a history of CABG or PCI.
  - Fatigue (overwhelming sense of exhaustion causing a decreased capacity for physical activity or mental work).
- II. The Diamond Forrester pre-test probability of CAD is a statistical tool used in the initial assessment of stable chest pain syndromes to estimate the likelihood that the symptoms are caused by obstructive coronary artery disease using the individual's description of the symptoms, their age, and sex assigned at birth.
- Link to calculator: [https://qxmd.com/calculate/calculator\\_32/pretest-probability-of-cad](https://qxmd.com/calculate/calculator_32/pretest-probability-of-cad)

## **DESCRIPTION**

Computed tomographic angiography, or CTA, is a non-invasive imaging test that requires the use of intravenously administered contrast material and high-resolution, high-speed CT machinery to obtain detailed volumetric images of blood vessels. CTA can be applied to image blood vessels throughout the body; however, to apply CTA in the coronary arteries, several technical challenges must be overcome, to obtain high-quality diagnostic images. Short image acquisition times are necessary, to avoid blurring artifacts from the rapid motion of the beating heart. In some cases, premedication with beta-blocking agents is used to slow the heart rate below 60-65 beats per minute, to facilitate adequate scanning, and electrocardiographic triggering or retrospective gating is used to obtain images during diastole when motion is reduced. Rapid scanning is also helpful, so that the volume of cardiac images can be obtained during breath-holding. Very thin sections (less than 1 mm) are important to provide adequate spatial resolution and high-quality three-dimensional reconstruction images.

Cardiac CTA has been proposed as a noninvasive alternative to invasive coronary angiography (ICA). Applications include, but are not limited to, evaluation of obstructive coronary artery disease (CAD), coronary artery bypass graft patency, coronary artery stent patency, coronary artery aneurysm, delineation of coronary artery anomaly, and functional cardiac assessment.

Fractional flow reserve (FFR) is the ratio between the maximum blood flow in a narrowed artery and the maximum blood flow in a normal artery. The HeartFlow FFRCT (HeartFlow, Inc., Redwood City, CA) is coronary physiologic simulation software that has been approved by the U.S. Food and Drug Administration (FDA) to provide a non-invasive method of estimating FFR using standard coronary CTA image data.

Automated quantification and characterization of coronary atherosclerotic plaque is a service in which coronary computed tomographic angiography (CTA) data are analyzed using computerized algorithms to assess the extent and severity of coronary artery disease. The use of automated quantification and characterization of coronary atherosclerotic plaque is considered investigational at this time.

## **RATIONALE**

Contrast-enhanced cardiac CTA can be performed using either multidetector-row CT (MDCT) or electron beam CT (EBCT). Multiple manufacturers have received Section 510(k) clearance from the FDA to market MDCT machines equipped with at least 16 detector rows, and at least two models of EBCT machines have been cleared by the FDA under Section 510(k). Intravenous iodinated contrast agents used for cardiac CTA have also received FDA approval.

Prospective studies with small sample sizes reflect that cardiac CTA is a promising noninvasive method for assessment of coronary stents, detection of in-stent restenosis and occlusion, and evaluating bypass patency. Studies with small sample sizes also conclude that the presence of myocardial hypoenhancement on cardiac CTA in acute chest pain patients has a high-positive predictive value and specificity, but only moderate sensitivity for presence of acute or healed MI. Additional

## **Medical Policy: CARDIAC/CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY (CARDIAC/CORONARY CTA): CONTRAST-ENHANCED**

**Policy Number: 6.01.34**

**Page: 5 of 9**

studies conclude that the presence and size of early perfusion defects and late enhancement on cardiac CTA is closely related to follow-up segment myocardial dysfunction and myocardial functional recovery. Available studies recommend that further studies be conducted, to evaluate the clinical value of these preliminary findings in larger patient populations.

Current studies consist of patient populations with a high pretest probability of CAD. Patients providing suboptimal images are often excluded from calculations of test accuracy. Future studies will need to examine these tests in larger, less-selected populations representing the clinical settings in which they are expected to be used.

Guidelines for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on clinical Practice Guidelines (Gulati et al., 2021) provides recommendations and algorithms for clinicians to assess and diagnose chest pain in adult patients. The recommendations are as follows:

- For intermediate-risk patients with acute chest pain and no known CAD eligible for diagnostic testing after a negative or inconclusive evaluation for Acute Coronary Syndrome (ACS), CCTA is useful for exclusion of atherosclerotic plaque and obstructive CAD (1A recommendation).
- For intermediate-risk patients with acute chest pain and known nonobstructive CAD, CCTA can be useful to determine progression of atherosclerotic plaque and obstructive CAD (2a recommendation).
- For intermediate-high risk patients with stable chest pain and no known CAD, CCTA is effective for diagnosis of CAD, for risk stratification, and for guiding treatment decisions (1A recommendation).
- For intermediate-high risk patients with stable chest pain after an inconclusive or abnormal exercise ECG or stress imaging study, CCTA is reasonable (2a recommendation).
- For patients who have stable chest pain with previous coronary revascularization, CCTA is reasonable to evaluate bypass graft or stent patency (for stents  $\geq 3$  mm) (2a recommendation).
- For patients who have had prior CABG surgery presenting with stable chest pain who are suspected to have myocardial ischemia, it is reasonable to perform stress imaging or CCTA to evaluate for myocardial ischemia or graft stenosis or occlusion (2a recommendation).
- For symptomatic patients with known nonobstructive CAD who have stable chest pain, CCTA is reasonable for determining atherosclerotic plaque burden and progression to obstructive CAD, and guiding therapeutic decision-making (2a recommendation)

The 2018 American Heart Association (AHA)/American College of Cardiology (ACC) Guidelines for the management of Adults with Congenital Heart Disease recommendations are as follows:

- CCT imaging can be useful in patients with adult congenital heart disease (ACHD) when information that cannot be obtained by other diagnostic modalities is important enough to justify the exposure to ionizing radiation (2a recommendation).
- Cardiovascular magnetic resonance (CMR), CCT, and/or transesophageal echocardiography (TEE) are useful to evaluate pulmonary venous connections in adults with ASD (1 recommendation).

In 2017, the National Institute for Health and Care Excellence (NICE) endorsed non-invasive FFR using coronary CTA (FFR-CT), stating, "The committee concluded that the evidence suggests that HeartFlow FFRCT is safe, has high diagnostic accuracy, and that its use may avoid the need for invasive investigations." For correct use, HeartFlow FFRCT requires access to 64-slice (or above) coronary CT angiography facilities. The American College of Cardiology CathPCI Registry (Messenger et al., 2017) also announced that it will allow FFRCT as an acceptable noninvasive method of documenting ischemia around the time of revascularization. Documentation of ischemia around the time of revascularization is important to the appropriate use criteria (AUC) for percutaneous coronary interventions (PCI).

### **CODES**

- *Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.*
- ***CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.***
- *Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.*

**Medical Policy: CARDIAC/CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY  
(CARDIAC/CORONARY CTA): CONTRAST-ENHANCED**

**Policy Number: 6.01.34**

**Page: 6 of 9**

- *Code Key: Experimental/Investigational = (E/I), Not medically necessary/appropriate = (NMN)*

**CPT Codes**

<b>Code</b>	<b>Description</b>
75572	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)
75573	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology in the setting of congenital heart disease (including 3D image postprocessing, assessment of left ventricular (LV) cardiac function, right ventricular (RV) structure and function and evaluation of vascular structures, if performed)
75574	Computed tomographic angiography, heart, coronary arteries and bypass grafts (when present), with contrast material, including 3D image postprocessing (including evaluation of cardiac structure and morphology, assessment of cardiac function, and evaluation of venous structures, if performed)
75580	Noninvasive estimate of coronary fractional flow reserve (FFR) derived from augmentative software analysis of the data set from a coronary computed tomography angiography, with interpretation and report by a physician or other qualified health care professional ( <i>effective 01/01/2024</i> )
0623T (E/I)	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission, computerized analysis of data, with review of computerized analysis output to reconcile discordant data, interpretation and report
0624T (E/I)	data preparation and transmission
0625T (E/I)	computerized analysis of data from coronary computed tomographic angiography
0626T (E/I)	review of computerized analysis output to reconcile discordant data, interpretation and report

*Copyright © 2023 American Medical Association, Chicago, IL*

**HCPCS Codes**

<b>Code</b>	<b>Description</b>
No specific code(s)	

**ICD10 Codes**

<b>Code</b>	<b>Description</b>
Numerous codes	

**REFERENCES**

Ates AH, et al. Long-term prognostic value of coronary atherosclerotic plaque characteristics assessed by computerized tomographic angiography. *Angiology* 2021;72(3):252-259.

**Medical Policy: CARDIAC/CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY  
(CARDIAC/CORONARY CTA): CONTRAST-ENHANCED**

**Policy Number: 6.01.34**

**Page: 7 of 9**

\*Bluemke DA, et al. Noninvasive coronary artery imaging. Magnetic resonance angiography and multidetector computed tomography angiography. A scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention, and the Councils on Clinical Cardiology and Cardiovascular Disease in the Young. Circulation 2008 Jul 29;118(5):586-606.

Cerrato E, et al. Revascularization deferral of nonculprit stenoses on the basis of fractional flow reserve: 1-year outcomes of 8,579 patients. JACC Cardiovasc Interv 2020 Aug 24;13(16):1894-1903.

Cheng XS, et al. Coronary Computed Tomography Angiography in Diagnosing Obstructive Coronary Artery Disease in Patients with Advanced Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Cardiorenal Med 2021;11(1):44-51.

Cheng XS, et al. Emerging evidence on coronary heart disease screening in kidney and liver transplantation candidates: a scientific statement from the American Heart Association. Circulation 2022 Oct. 146:e299–e324.

Dewey M, et al. CT or invasive coronary angiography in stable chest pain: the DISCHARGE trial group. New England Journal of Medicine 2022; DOI: 10.1056/NEJMoa2200963.

\*Earls JP, et al. ACR Appropriateness Criteria® chronic chest pain – high probability of coronary artery disease. J Am Coll Radiol 2011 Oct;8(10):679-86.

\*Fihn SD, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012; 60(24):e44-e164.

\*Gershin E, et al. 16-MDCT coronary angiography versus invasive coronary angiography in acute chest pain syndrome: a blinded prospective study. AJR Am J Roentgenol 2006 Jan;186(1):177-84.

\*Goldstein JA, et al. The CT-STAT (Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment) trial. J Am Coll Cardiol 2011 Sep;58(14):1414-22.

Gulati M, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/ SCCT/SCMR Guideline for the evaluation and diagnosis of chest pain. J Am Coll Cardiol 2021;78(22):e187-e285.

\*Hamilton-Craig C, et al. Diagnostic performance and cost of CT angiography versus stress ECG- a randomized prospective study of suspected acute coronary syndrome chest pain in the emergency department (CT-COMPARE). In J Cardiol 2014 Oct 22;177(3):867-73.

Halvorsen S, et al. ESC Scientific Document Group. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J 2022 Oct 14;43(39):3826-3924.

\*Hoffmann U, et al. Coronary computed tomography angiography for early triage of patients with acute chest pain. J Am Coll Cardiol 2009;53(18):1642–50.

\*Hulten E, et al. Outcomes after coronary computed tomography angiography in the emergency department; a systematic review and meta-analysis of randomized, controlled trials. J Am Coll Cardiol 2013;61(8):880-92.

\*Hulten EA, et al. Prognostic evaluation of cardiac computed tomography angiography: a systematic review. J Am Coll Cardiol 2011;57(10):1237-47.

Jaltotage B, et al. Coronary computed tomographic angiography derived findings and risk score improves the allocation of lipid lowering therapy compared to clinical score. Medicine 2022;101(6).

\*Jones RL, et al. Safe and rapid disposition of low-to-intermediate risk patients presenting to the emergency department with chest pain: a 1-year high-volume single-center experience. J Cardiovasc Comput Tomogr 2014 Sep-Oct;8(5):375-83.

**Medical Policy: CARDIAC/CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY  
(CARDIAC/CORONARY CTA): CONTRAST-ENHANCED**

**Policy Number: 6.01.34**

**Page: 8 of 9**

Ko BS, et al. Non-invasive CT-derived fractional flow reserve and static rest and stress CT myocardial perfusion imaging for detection of haemodynamically significant coronary stenosis. The International Journal of Cardiovascular Imaging 2019; 35:2103-2112.

Korsholm K, et al. Expert recommendations on cardiac computed tomography for planning transcatheter left atrial appendage occlusion. J Am Coll Cardiol Intv 2020;13:277-292.

\*Linde JJ, et al. Cardiac computed tomography guided treatment strategy in patients with recent acute-onset chest pain: results from the randomised, controlled trial: CARDiac cT in the treatment of acute CHEst pain (CATCH). Int J Cardiol 2013 Oct 15;168(6):5257-62.

Lowenstern A, et al. Age-Related Differences in the Noninvasive Evaluation for Possible Coronary Artery Disease: Insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) Trial. JAMA Cardiology 2020;5(2):193-201.

\*Löffler AI, et al. Coronary Computed Tomography Angiography Demonstrates a High Burden of Coronary Artery Disease Despite Low-Risk Nuclear Studies in Pre-Liver Transplant Evaluation. Liver Transpl 2020 Nov;26(11):1398-1408.

Matsumoto H, et al. Standardized volumetric plaque quantification and characterization from coronary CT angiography: a head-to-head comparison with invasive intravascular ultrasound. Eur Radiol 2019 Nov;29(11): 6129–6139.

Mehta P, et al. Major adverse cardiac events after emergency department evaluation of chest pain patients with advanced testing: Systematic review and meta-analysis. Acad Emerg Med 2021;00:1-17.

\*McKavanagh P, et al. A comparison of cardiac computerized tomography and exercise stress electrocardiogram test for the investigation of stable chest pain: the clinical results of the CAPP randomized prospective trial. Eur Heart J Cardiovasc Imaging 2015 Apr;16(4):441-8.

\*Muhlestein JB, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA 2014 Dec 3;312(21):2234-43.

National Institute for Health and Care Excellence. HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography [MTG32]. Published Feb 2017/Updated May 2021; [<https://www.nice.org.uk/guidance/mtg32>] accessed 11/08/23.

\*Nielsen LH, et al. The diagnostic accuracy and outcomes after coronary computed tomography angiography vs conventional functional testing in patients with stable angina pectoris: a systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging 2014 Sep;15(9):961-71.

\*Park GM, et al. Coronary computed tomographic angiographic findings in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol 2014 Mar 1;113(5):765-71.

\*Park JK, et al. Multidetector computed tomography for the evaluation of coronary artery disease; the diagnostic accuracy in calcified coronary arteries, comparing with IVUS imaging. Yonsei Med J 2014 May 1;55(3):599-605.

Patel MR, et al. 1-Year Impact on Medical Practice and Clinical Outcomes of FFRCT: The ADVANCE Registry. JACC: Cardiovascular Imaging 2020 Jan;13:97-105.

\*Sara L, et al. Accuracy of multidetector computed tomography for detection of coronary artery stenosis in acute coronary syndrome compared with stable coronary disease: A CORE64 multicenter trial substudy. Int J Cardiol 2014 Dec 15;177(2):385-91.

Shah AB, et al. ACR Appropriate Criteria Chronic Chest Pain-Noncardiac Etiology Unlikely-Low to Intermediate Probability of Coronary Artery Disease. J Am Coll Radiol 2018 Nov;15(11S):S283-S290.

Sharma A, et al. Stress testing versus CT angiography in patients with diabetes and suspected coronary artery disease. J Am Coll Cardiol 2019 Mar;73(8):893-902.



**Medical Policy: CARDIAC/CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY  
(CARDIAC/CORONARY CTA): CONTRAST-ENHANCED**

**Policy Number: 6.01.34**

**Page: 9 of 9**

\*Stout KK, et al. 2018 AHA/ACC Guideline for the management of adults with congenital heart disease: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol 2019;73(12):1494-1563.

\*Sun Z, et al. Coronary CT angiography: current status and continuing challenges. Br J Radiol 2012 May;85(1013):495-510.

\*Taylor AJ, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography: A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, The American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol 2010;56:1864-94.

Truong QA, et al. Coronary computed tomography imaging in women: an expert consensus statement from the Society of Cardiovascular Computed Tomography. J Cardiovasc Comput Tomogr 2018 Nov-Dec;12(6):451-466.

\*Wever-Pinzon O, et al. Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy: a meta-analysis of prospective trials. J Am Coll Cardiol 2014;63(19):1992-2004.

Wieske V, et al. Computed tomography angiography versus Agatston score for diagnosis of coronary artery disease in patients with stable chest pain: individual patient data meta-analysis of the international COME-CCT Consortium. European Radiology (2022) 32:523-5245.

\*Wolk MJ, et al. ACCF/AHA/ASE/ASNC/HFSA/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Card Fail 2014 Feb;20(2):65-90.

\*Zeb I, et al. Coronary computed tomography as a cost-effective test strategy for coronary artery disease assessment- a systematic review. Atherosclerosis 2014 Feb 24;234(2):426-435.

\*Key Article

**KEY WORDS**

Cardiac CTA, Coronary artery CTA, calcium scoring.

**CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS**

There is currently a Local Coverage Determination (LCD) for Cardiac Computed Tomography (CCT) and Coronary Computed Tomography Angiography (CCTA) (L33559). Please refer to the following LCD website for Medicare members:

[\[https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33559&ver=28&CtrctrSelected=298\\*1&Ctrctr=298&s=41&DocType=2&bc=AAgAAAQBAAAA&=\]](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33559&ver=28&CtrctrSelected=298*1&Ctrctr=298&s=41&DocType=2&bc=AAgAAAQBAAAA&=) accessed 11/08/23.